Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 6/20 | 0.44 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | LSS | P48449 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.32 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23887638 | 0.76 | SRD5A2 (0.43) | SRD5A2SRD5A1HDAC2S1PR1LSS | |
| SCHEMBL23887668 | 0.76 | SRD5A2 (0.43) | SRD5A2SRD5A1 | |
| SCHEMBL20305039 | 0.73 | ALDH1A1 (0.46) | SRD5A2MAPTALDH1A1 | |
| SCHEMBL19995444 | 0.68 | KMT2A (0.40) | SRD5A2MAPTALDH1A1 | |
| SCHEMBL6082641 | 0.68 | ALDH1A1 (0.46) | SRD5A2S1PR1ALDH1A1 | |
| SCHEMBL6082644 | 0.68 | ALDH1A1 (0.46) | SRD5A2S1PR1ALDH1A1 | |
| SCHEMBL17750085 | 0.66 | LSS (0.51) | SRD5A2SRD5A1L3MBTL1LSS | |
| SCHEMBL14720788 | 0.66 | SRD5A2 (0.48) | SRD5A2SRD5A1 | |
| SCHEMBL19994676 | 0.66 | SRD5A2 (0.48) | SRD5A2SRD5A1ALDH1A1 | |
| SCHEMBL2257950 | 0.66 | SRD5A2 (0.54) | SRD5A2SRD5A1HDAC2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673879-B2 | Substituted pyrimidines and methods of use | ALK, TYMP, ENTPD5 | SRD5A2 1826/4885SRD5A1 1492/4885HDAC2 4095/4885 |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | SRD5A2 1826/4885SRD5A1 1492/4885HDAC2 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.